TP53 and glioblastoma: DXM appears to interfere with p53-dependent pathways of drug toxicity since the glioblastoma cell lines (LN-229 and U87MG) with wild-type p53 status were protected from drug toxicity by DXM to a greater extent than the cell lines (LN-18, LN-308, and T98G) with mutant p53 [3-5].